JP2019512495A - 急性骨髄性白血病の治療のための併用療法 - Google Patents

急性骨髄性白血病の治療のための併用療法 Download PDF

Info

Publication number
JP2019512495A
JP2019512495A JP2018548236A JP2018548236A JP2019512495A JP 2019512495 A JP2019512495 A JP 2019512495A JP 2018548236 A JP2018548236 A JP 2018548236A JP 2018548236 A JP2018548236 A JP 2018548236A JP 2019512495 A JP2019512495 A JP 2019512495A
Authority
JP
Japan
Prior art keywords
salt
amino
acute myeloid
myeloid leukemia
methylpiperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018548236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512495A5 (enExample
Inventor
エルクット バーチェジ
エルクット バーチェジ
陽子 山木
陽子 山木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of JP2019512495A publication Critical patent/JP2019512495A/ja
Publication of JP2019512495A5 publication Critical patent/JP2019512495A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018548236A 2016-03-29 2017-03-27 急性骨髄性白血病の治療のための併用療法 Pending JP2019512495A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662314700P 2016-03-29 2016-03-29
US62/314700 2016-03-29
US201662368343P 2016-07-29 2016-07-29
US62/368343 2016-07-29
PCT/JP2017/012293 WO2017170348A1 (en) 2016-03-29 2017-03-27 Combination therapy for the treatment of acute myeloid leukemia

Publications (2)

Publication Number Publication Date
JP2019512495A true JP2019512495A (ja) 2019-05-16
JP2019512495A5 JP2019512495A5 (enExample) 2020-04-09

Family

ID=59965623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018548236A Pending JP2019512495A (ja) 2016-03-29 2017-03-27 急性骨髄性白血病の治療のための併用療法

Country Status (10)

Country Link
US (2) US20190117649A1 (enExample)
EP (1) EP3436014A4 (enExample)
JP (1) JP2019512495A (enExample)
KR (1) KR20180124055A (enExample)
CN (1) CN108883109A (enExample)
BR (1) BR112018069111A2 (enExample)
CA (1) CA3018155A1 (enExample)
MX (1) MX2018011975A (enExample)
RU (1) RU2018134167A (enExample)
WO (1) WO2017170348A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
EA202191984A1 (ru) * 2019-02-22 2021-11-19 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза
PH12021551985A1 (en) 2019-02-22 2022-08-22 Hanmi Pharmaceutical Co Ltd Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
PL3949952T3 (pl) 2019-04-03 2024-10-14 Astellas Pharma Inc. Kompozycja farmaceutyczna
KR20210002015A (ko) 2019-06-27 2021-01-06 한미약품 주식회사 Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
CN114728004A (zh) * 2019-10-14 2022-07-08 阿斯利康(瑞典)有限公司 用于治疗恶性血液病的组合疗法
CN114828842A (zh) * 2019-10-21 2022-07-29 理森制药股份公司 用于治疗急性髓系白血病的包含dhodh抑制剂的组合物
JP2025502748A (ja) 2021-12-30 2025-01-28 バイオメア フュージョン，インコーポレイテッド Ｆｌｔ３の阻害剤としてのピラジン化合物
KR102559124B1 (ko) 2022-08-25 2023-07-26 주식회사 엔젠바이오 Flt3 유전자 증폭용 조성물 및 이의 용도

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 128, no. 22, JPN6020049994, 2 December 2016 (2016-12-02), pages 2830, ISSN: 0004417084 *
EXPERT REVIEW OF HEMATOLOGY, vol. 9, no. 5, JPN6020049991, 17 March 2016 (2016-03-17), pages 433 - 445, ISSN: 0004563950 *
LEUKEMIA, vol. 30, JPN6020049993, 15 January 2016 (2016-01-15), pages 1025 - 1032, ISSN: 0004563951 *

Also Published As

Publication number Publication date
CA3018155A1 (en) 2017-10-05
EP3436014A1 (en) 2019-02-06
KR20180124055A (ko) 2018-11-20
US20190117649A1 (en) 2019-04-25
BR112018069111A2 (pt) 2019-03-19
EP3436014A4 (en) 2019-11-27
RU2018134167A3 (enExample) 2020-06-30
WO2017170348A1 (en) 2017-10-05
CN108883109A (zh) 2018-11-23
US20200360372A1 (en) 2020-11-19
RU2018134167A (ru) 2020-04-29
MX2018011975A (es) 2019-01-15

Similar Documents

Publication Publication Date Title
JP2019512495A (ja) 急性骨髄性白血病の治療のための併用療法
Khandelwal et al. Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic stem cell transplant patients
Welschinger et al. Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice
JP6759402B2 (ja) Ｆｌｔ３変異を有する急性骨髄性白血病の治療用の医薬組成物
US8003105B2 (en) Method of treating cancer by co-administration of anticancer agents
TWI759316B (zh) Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物
JP2009102408A (ja) ホモハリングトニンを単独で、または他の薬剤と組み合わせて用いる、ｓｔｉ５７１に耐性または不耐性の慢性骨髄性白血病の治療
Davids et al. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies
KR20200083532A (ko) 적어도 1종의 스플라이세오솜 조정제, 및 bcl2 억제제, bcl2/bclxl 억제제 및 bclxl 억제제로부터 선택된 적어도 1종의 억제제를 포함하는 조합물 및 사용 방법
WO2016168451A1 (en) Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment
Hughes et al. Treatment of patients with relapsed/refractory non-hodgkin lymphoma with venetoclax: a single-center evaluation of off-label use
WO2022090443A1 (en) Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
KR20160113302A (ko) 호중구감소증을 치료하기 위한 조성물 및 방법
JPWO2019016928A1 (ja) がん細胞の代謝の特異性に基づく新規抗悪性腫瘍剤
Agrawal et al. Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the “best” therapy?
RU2746705C2 (ru) Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции
EP2928456B1 (en) Treatment of hematological cancer refractory to an anti-cancer agent
JP2021063014A (ja) 白血病治療薬
US20190183893A1 (en) Low dose of sildenafil as an antitumor drug
EP3641775B1 (en) Combination of a mcl-1 inhibitor and a standard of care treatment for hematologic cancers, uses and pharmaceutical compositions thereof
Smith et al. Differentiation therapy in poor risk myeloid malignancies: results of a dose finding study of the combination bryostatin-1 and GM-CSF
WO2021079129A1 (en) Dosing regimen
CN111228264A (zh) 西达本胺联合cgb以及自体造血干细胞的应用及联合药物
CN116390735A (zh) 治疗癌症的Bcl-2抑制剂和低甲基化剂的组合、其用途和药物组合物
MAH et al. Effects of pentoxifylline on in vivo leukocyte function and clearance of group B streptococci from preterm rabbit lungs

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210427

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210803